Core Insights - Veeva Systems has announced that Novo Nordisk's International Operations business unit will implement Veeva Vault CRM to enhance its commercial capabilities with advanced AI technology [1][2][3] Group 1: Partnership and Technology - The partnership between Veeva and Novo Nordisk aims to leverage AI-driven technology to improve the delivery of innovative medicines for chronic diseases [2] - Vault CRM is designed to support effective commercial execution across both personal and digital channels, addressing specific business and compliance needs in various countries [2][3] Group 2: Company Overview - Veeva Systems provides cloud-based solutions for the life sciences industry, serving over 1,500 customers, including major biopharmaceutical companies and emerging biotech firms [4] - The company is committed to innovation and balancing the interests of all stakeholders, including customers, employees, and shareholders [4]

Veeva Systems Inc. (NYSE:VEEV) is one of the best healthcare AI stocks to buy now. On December 15, Stifel reiterated a Buy rating on Veeva Systems Inc. (NYSE:VEEV), even as some big pharmaceutical customers shift away from its legacy CRM platform. Stifel sees these migrations as a small, manageable issue that won’t derail Veeva’s overall momentum. Stifel Maintains Buy on Veeva (VEEV) Despite CRM Customer Migrations According to the analyst’s assessment, Veeva currently serves 18 of the top 20 pharmaceuti ...

Core Insights - Roche Pharmaceuticals has chosen to extend its partnership with Veeva Systems by adopting Veeva Vault CRM, which is expected to enhance customer engagement through AI capabilities [1][2]. Company Overview - Veeva Systems provides industry cloud solutions for life sciences, offering software, data, and business consulting services to over 1,500 customers, including major biopharmaceutical companies and emerging biotech firms [3]. Partnership Details - The partnership extension will implement Vault CRM across Roche's global Pharma organization, aiming to create more personalized interactions and provide insights to better support healthcare professionals and patients [2]. - Veeva AI, which includes various agentic AI features, will be integrated into the Vault CRM platform, with specific agents like Free Text Agent, Voice Agent, Pre-call Agent, and Media Agent expected to be available in December 2025 [2].

Core Insights - Veeva Systems Inc. reported total revenues of $811.2 million for the third quarter of fiscal 2026, representing a 16% increase year over year. Subscription services revenues were $682.5 million, up 17% year over year [1][9] - The company is on track to achieve its 2030 revenue run-rate goal of $6 billion, with strong performance across its business segments [2][9] - Veeva AI is advancing rapidly, with early adopter projects showing significant value in specialized AI applications for the life sciences industry [2] Financial Performance - Total revenues for the third quarter were $811.2 million, up from $699.2 million a year ago, marking a 16% increase [9] - Subscription services revenues increased to $682.5 million from $580.9 million, a 17% year-over-year growth [9] - Operating income for the third quarter was $240.9 million, a 33% increase from $181.4 million year over year [9] - Non-GAAP operating income was $364.9 million, up 20% from $304.0 million year over year [9] - Net income for the third quarter was $236.2 million, a 27% increase from $185.8 million year over year [9] - Non-GAAP net income was $345.1 million, up 20% from $288.3 million year over year [9] - Fully diluted net income per share was $1.40, compared to $1.13 a year ago, while non-GAAP fully diluted net income per share was $2.04, up from $1.75 [9] Strategic Developments - Veeva AI is set to release its first specialized AI agents for CRM and commercial content in early December, with additional agents planned for 2026 [9] - The company added 23 new customers to its Vault CRM platform, bringing the total to 115 customers live, including a significant rollout in Japan for a top 20 biopharma [9] - Veeva Development Cloud has been selected as the enterprise standard by three top 20 biopharmas, indicating strong demand for its applications [9] Guidance and Outlook - Veeva provided guidance for its fiscal fourth quarter ending January 31, 2026, expecting total revenues between $807 million and $810 million [3] - For the full fiscal year ending January 31, 2026, Veeva expects total revenues between $3,166 million and $3,169 million [3]

Core Insights - Veeva Systems Inc. (VEEV) is positioned for growth due to its strong product portfolio and solid second-quarter fiscal 2026 performance, despite concerns over rising operational costs [1][8]. Financial Performance - Veeva Systems reported a revenue increase of 16.7% year over year, reaching $789 million in Q2, surpassing its guidance [5][8]. - The company has a market capitalization of $46.89 billion and anticipates a 23.5% growth over the next five years, with a trailing four-quarter average earnings surprise of 9.7% [3][5]. Growth Drivers - The robust product portfolio includes continued subscription momentum in Vault CRM, which is now adopted by nine of the top 20 pharmaceutical firms [5][10]. - The Development Cloud has shown steady expansion, with subscriptions growing at the fastest pace in two years, particularly in clinical, regulatory, and quality solutions [6][10]. - Crossix and Data Cloud offerings are key growth drivers, enhancing Veeva's integrated ecosystem in the life sciences industry [7][9]. Strategic Initiatives - Recent strategic deals with Gilead and IQVIA have strengthened Veeva's position in the life sciences sector, facilitating seamless integration of data within its Commercial and Development Clouds [9][10]. - The rollout of Veeva AI is part of the company's strategy to enhance its offerings, with initial releases planned for December and broader expansion through 2027 [12]. Cost Considerations - Operating expenses increased by 17.3% year over year, with general and administrative expenses rising by 56.1% in Q2 fiscal 2026 [13][14]. - Management anticipates further increases in sales and marketing expenses due to workforce expansion to support growth initiatives [13][14]. Estimate Trends - The Zacks Consensus Estimate for fiscal 2026 earnings per share has increased by 15 cents to $7.68, with Q3 fiscal 2026 revenue estimates at $791.9 million, reflecting a 13.3% year-over-year improvement [15].

Core Insights - Veeva Systems Inc. is recognized as one of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years, highlighting its strong market position and growth potential [1] - The company is expanding its influence in the life sciences industry through its cloud-based platforms, serving over 1,500 global customers [1] - Veeva Systems operates as a Public Benefit Corporation, indicating a commitment to balancing stakeholder interests [1] Financial Performance - Veeva Systems reported a revenue increase of 16.7% year-over-year, with a free cash flow of approximately $1.18 billion as of August 22 [3] - The company reinvests its free cash flow into growth initiatives rather than distributing dividends [3] - Analysts project an average price target suggesting nearly 14% upside, with a forward P/E ratio indicating confidence in continued double-digit revenue growth [3] Strategic Developments - Bristol Myers Squibb's adoption of Veeva Vault CRM strengthens Veeva's market position and reflects growing confidence in its offerings [2][4] - The company is focusing on the increasing demand for digital transformation in healthcare, integrating AI capabilities into its platforms [4] - Veeva Systems is positioning itself as a leader in cloud-based, generative AI-enabled solutions for pharmaceutical and biotechnology clients [4] Future Outlook - Veeva Systems will host a Virtual Investor Day on October 16, 2025, to outline future strategies and product innovations [2]

Core Points - Veeva Systems will host its 2025 Investor Day virtually on October 16, 2025, from 1:30 p.m. PT to approximately 3:30 p.m. PT [1] - The event will be broadcast live on the company's investor relations website, with an archived webcast available afterward [1] Company Overview - Veeva Systems provides industry cloud solutions for life sciences, including software, data, and business consulting [2] - The company serves over 1,500 customers, including major pharmaceutical companies and emerging biotechs [2] - As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, and shareholders [2] Disclosure Practices - Veeva utilizes its investor relations website to disclose material non-public information and announce upcoming investor conferences [3] - Stakeholders are encouraged to monitor the investor relations website along with press releases and SEC filings for updates [3]

Core Insights - Bristol Myers Squibb (BMS) has committed to using Veeva Vault CRM to enhance customer engagement and decision-making in healthcare [1][2][3] Company Developments - Veeva Systems announced the partnership with BMS, highlighting the integration of AI into the customer journey to improve healthcare practitioner engagement [2][3] - The first Veeva AI agents for Vault CRM, including Pre-call Agent, Content Agent, Free Text Agent, and Voice Agent, are expected to be available in December 2025 [3] Industry Impact - The collaboration aims to transform how healthcare practitioners access information about innovative medicines, thereby supporting BMS's mission to deliver life-changing treatments to patients [2][3] - Veeva Systems serves over 1,500 customers in the life sciences sector, indicating a strong market presence and commitment to innovation [4]

Core Insights - Gilead Sciences has committed to using Veeva Vault CRM, enhancing their long-standing partnership with Veeva Systems [1][2][7] - Veeva Vault CRM is designed to improve commercial execution through advanced AI capabilities, including pre-call planning and voice control [2][3] Company Overview - Veeva Systems provides cloud-based software and services tailored for the life sciences industry, serving over 1,500 customers, including major biopharmaceutical companies [3] - Gilead Sciences is a biopharmaceutical company focused on innovative medicines for life-threatening diseases, operating in over 35 countries [4]

Core Insights - Boehringer Ingelheim has standardized customer data across over 100 countries using Veeva OpenData and Veeva Network, enhancing their ability to engage healthcare professionals with relevant information and laying the groundwork for AI scalability [1][2] Group 1: Partnership and Strategy - The partnership with Veeva aims to strengthen customer engagement and facilitate future AI applications, providing a unified customer view for Boehringer Ingelheim's field and brand teams [2] - By consolidating its data strategy into a single comprehensive solution, Boehringer Ingelheim is simplifying data management and improving efficiencies, ensuring quick access to high-quality customer data [2][3] Group 2: Technology and Integration - Veeva's integrated solution, which includes Vault CRM, OpenData, and Network, is designed to connect data, enhance healthcare professional engagement, and drive AI innovation at scale [3] - Veeva OpenData is part of the broader Veeva Data Cloud, which encompasses various tools aimed at improving collaboration among sales, marketing, and medical teams [3] Group 3: Company Overview - Veeva Systems is recognized as a global leader in cloud software for the life sciences sector, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotech firms [4]